Perelman School of Medicine at the University of Pennsylvania

Topic:  An Update from the XIX International AIDS Conference and 52nd ICAAC

Speaker:  Ian Frank, MD


Register

HIV Grand Rounds from the Perelman School of Medicine at the University of Pennsylvania: September 20, 2012
Your name *
Email address *
Degree/Profession *
Country *
How many participants are watching using your internet connection? *
I would like CME Credit for this program and have reviewed the CME information below. * Yes No
 
* Required

ATTENTION: After selecting a session to view you will be taken to a short form. If you have logged on to ViralEd.com the form will be prepopulated where only one question, related to the number of participants, is left blank. Once this short form has been filled out and the "Go To Program" button has been pressed you will be taken directly to the program, which will commence immediately.

If you desire CME credit for viewing this session, and have not established a UPenn CME account, please procede to http://penncmeonline.com/user/register.

Create your account and then you will receive an email with your initial login information. Follow the link in the email to change your password and complete the one-time profile set up. Once this is finished, your UPenn CME account will enable you to receive credit for this and all subsequent sessions by simply texting the session specific CME code following each grand rounds. 
 

Jointly Sponsored by Perelman School of Medicine Small JPEG and VE logo 300px

Series Overview:

The Perelman School of Medicine at the University of Pennsylvania and ViralEd are proud to announce the extension of this ground-breaking CME activity. Mirroring academic grand rounds programs, these CME-certified sessions combine traditional academic grand rounds with the innovation and convenience of telemedicine. The "HIV Grand Rounds from the Perelman School of Medicine at the University of Pennsylvania" is delivered live via the Internet every Thursday at noon (12 PM) Eastern Time and is available for on-demand viewing twenty-four hours after the live broadcast.

Presentations cover the most important and current topics in HIV/AIDS and are delivered by the top experts in the field. They are designed to be immediately relevant to practicing HIV clinicians and many are case-based. The final 10 minutes of each one-hour educational activity consists of a live question and answer period, with the presenting faculty member available to answer questions asked by attendees using the webinar interface. These weekly grand rounds are intended to provide clinicians with convenient and easily accessible knowledge and clinical skills they need to provide the best medical care for their HIV-positive patients.

Each session may be broadcast via your Internet connection in your conference room or auditorium for large groups to view, or individually to your personal computer at your convenience. Simply register at www.viraled.com/grandrounds for easy access.

Target Audience:

This educational activity is designed for HIV specialists, Infectious Disease specialists, Internal Medicine specialists, Family Practice physicians, Dermatologists, Osteo-specialists, Nephrologists, Hematology/oncologist, Psychiatrists, Public Health professionals, OB/GYN physicians and other clinicians interested and involved in the care of patients with HIV/AIDS.

Commercial Support Acknowledgement:

These activities are supported by educational grants from Gilead Sciences and Janssen Therapeutics.

Learning Objectives for the Series: 

Upon completion of the educational activity, participants should be able to:

  • List the important factors that play a role in ARV therapy success;
  • Explain the role that drug adverse events, drug pharmacokinetics and patient adherence play in achieving ARV success and avoiding morbidity and mortality;
  • Describe the important opportunistic infections and co-morbidities that may affect HIV-positive patients and increase their risk for morbidity and mortality;
  • Discuss the importance of individualizing the care of each HIV-positive patient. 

Course Directors:
John Bartlett, MD
Professor of Medicine,
Johns Hopkins School of Medicine
Baltimore, Maryland
Calvin J. Cohen, MD, MS
Research Director,
CRI New England
Clinical Instructor,
Harvard Medical School
Boston, Massachusetts
Ian Frank, MD
Professor of Medicine,
Director, Antiretroviral Clinical Research
University of Pennsylvania
Philadelphia, Pennsylvania
 

Faculty:   
Ian Frank, MD
Professor of Medicine,
Director, Antiretroviral Clinical Research
University of Pennsylvania
Philadelphia, Pennsylvania
 

Accreditation Statement:

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Perelman School of Medicine at the University of Pennsylvania and ViralEd, LLC. The Perelman School of Medicine at the University of Pennsylvania is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

The Perelman School of Medicine at the University of Pennsylvania designates each live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures:

It is policy at the Perelman School of Medicine at the University of Pennsylvania and ViralEd, LLC for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships that they have with any commercial interest that provides products or services that may be relevant to the content of this continuing medical education activity. For this purpose we consider relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.

The intent of this policy is not to prevent expert faculty with relevant relationship(s) with commercial interest(s) from involvement in CME, but rather to ensure that Penn CME-certified activities promote quality and safety, are effective in improving medical practice, are based on valid content, and are independent of control from commercial interests and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information provided to the Penn Office of CME was found to contain relationships that created a conflict of interest relative to the topic of their presentation. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of CME at the Perelman School of Medicine at the University of Pennsylvania (Rodman Campbell, Mila Kostic, Belinda Rose, and Mindy Pollock Troy), our educational partner ViralEd, LLC (Richard Gordon, Brian Boyle, MD, JD and Ed Hettman), and the peer reviewer, Zalman Agus, MD, Associate Dean for Continuing Medical Education, have reported that they have no relevant financial relationships with any commercial interests related to the content of this educational activity.

The following faculty or planning committee members have disclosed that they have no relevant financial relationships with any commercial interests related to the content of this educational activity:

John Bartlett, MD      

The following faculty or planning committee members have reported the listed relevant financial relationships with commercial interests related to the content of this educational activity:

Name Commercial Supporter Relationship
Calvin Cohen, MD Gilead; Bristol-Myers Squibb; Merck & Co. Contracted Research
  Gilead; Bristol-Myers Squibb; Merck & Co.; Tobira Honoraria
     
     
Ian Frank, MD GlaxoSmithKline, Merck & Co. Contracted Research
  Gilead, Tibotec Consulting Fees
     
     
     
     
     
     

Disclosure of Unlabeled Use:

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. ViralEd, LLC, the Perelman School of Medicine at the University of Pennsylvania, Gilead Sciences and Janssen Therapeutics do not recommend the use of any agent outside of the labeled indications.

Presenter    Product Invetigational and/or Off-label Use
Ian Frank MD Dolutegravir Experimental Product in Phase 3 Trials
     

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of ViralEd, LLC, the Perelman School of Medicine at the University of Pennsylvania, Gilead Sciences and Janssen Therapeutics. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

Disclaimer:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.